First Phase of Sentinel Drug Safety Program Launched by FDA

February 2011
Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p94
Trade Publication
The article reports on the launch of the initial phase of the Food and Drug Administration's (FDA) Sentinel program for real time monitoring of drug safety problems which enables the agency in tracking health care events in 60 million Americans in the U.S.


Related Articles

  • FDA's Sentinel System Harnesses Big Data to Monitor Medical Products. Slabodkin, Greg // Healthdatamanagement.com;3/12/2015, p5 

    The article describes the U.S. Food and Drug Administration's (FDA) Sentinel active surveillance system for monitoring the safety of FDA-regulated drugs and other medical products. The initiative, which transitioned from a pilot program to a full-scale system, is deemed one of the largest uses...

  • FDA unveils new safety monitoring communication system.  // Hem/Onc Today;7/10/2010, Vol. 10 Issue 13, p34 

    The article reports on a drug and biologic safety monitoring communication system launched by the U.S. Food and Drug Administration (FDA).

  • Science, Surrogates & Stability. Wechsler, Jill // Pharmaceutical Executive;Jun99, Vol. 19 Issue 6, p18 

    Discusses the need to strengthen the science base of the United States Food and Drug Administration (FDA). Role of scientific expertise in a number of important regulatory initiatives; Why it is critical for the FDA to determine what data are needed to document the health benefit of a...

  • FDA's ability to affect treatment patterns appears limited.  // PharmacoEconomics & Outcomes News;2/20/2010, Issue 597, p4 

    The article discusses research by S. H. Busch et al published in the January 1, 2010 issue of the journal "Psychiatric Services" which discussed the ability of the U.S. Food and Drug Administration (FDA) to influence the care received by patients.

  • Washington update. Wechsler, Jill // Formulary;Jan1997, Vol. 32 Issue 1, p100 

    Focuses on health care issues facing the US Food & Drug Administration (FDA) for the year 1997. Appointment of new FDA commissioner; Continuation of the FDA user-fee program; Restoration of solvency to Medicare; Enactment of policies related to growth of managed care.

  • REMS Seen as Opportunity.  // Chain Drug Review;9/27/2010, Vol. 32 Issue 16, p93 

    The article focuses on the significance of the Risk Evaluation and mitigation Strategies (REMS) of the U.S. Food and Drug Administration (FDA).

  • FDA Seeks Comments on ICH's GCP Guideline Update.  // CenterWatch Monthly;Jan2016, Vol. 23 Issue 1, p4 

    The article presents the comments sought by the government agency the U.S. Food and Drug Administration (FDA) on the draft guidance entitled "Guideline for Good Clinical Practice."

  • Drug Accountability. Lieck, David J.; Bertram, Jason E. // Applied Clinical Trials;Mar2002, Vol. 11 Issue 3, p36 

    Examines the importance of drug accountability records with respect to data integrity in the U.S. Reference to the findings on a study conducted by the Food and Drug Administration; Description of drug shipment content; Steps involved in drug accountability process. INSET: Warning Letters.

  • Graham attacks FDA safety on TV show. Dickinson, Jack G. // Medical Marketing & Media;Mar2005, Vol. 40 Issue 3, p17 

    Reports that U.S. Food and Drug Administration (FDA) Office of Drug Safety deputy director David Graham has launched a scathing attack of the agency on PBS program "Now." Purpose of the launch of scathing attack; Provision of disturbing picture of the purported state of scientific dissent;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics